Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III RCT of SHR-1314 in adults with non-radiographic axial spondyloarthritis
CTR20250727Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of vunakizumab in axial spondyloarthritis (axSpA), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jun 2025; status: active.
02
Drugs
vunakizumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on CTR20250727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250727.